WEBINAR — Dec. 10, 2025 @ 11 AM ET
Integrated High-Throughput Platform for Functional Profiling of Myeloid Cells in Models of Pancreatic Cancer 

PhasED-Seq™ MRD Detection: Accurate & Early Cancer Monitoring

Foresight Diagnostics Logo

Nov 28, 2023

AURORA, Colo., Nov. 8, 2023 /PRNewswire/ – Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California. Four of these studies have been accepted as oral presentations. 

Read the full article on PR Newswire.